|
|
|
|
Appendix 4D Interim Financial Report
BRISBANE & MELBOURNE, 25 Febuary 2020
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D for the half year ending 31st December 2019.
Highlights for the period include:
- Successful completion of the preclinical program for the GaRP dietary supplement
- Finalisation of a draft protocol for a human clinical trial in irritable bowel syndrome (IBS) for the GaRP dietary supplement
- Exploring options to enhance the Company's marketing capability and build a pipeline of over-the-counter (OTC) gastrointestinal products
- Advancing discussions with multinational animal health partners to licence the Company's animal gut health product, Detach® - partnering deal expected by the end of FY 2020.
During the half year to 31 December 2019, the Company made significant steps towards taking its first human gastrointestinal health product, GaRP (Gastrointestinal ReProgramming dietary supplement), to market. Expenditure in furthering this effort resulted in a loss after tax of $1,803,324 for the period (December 2018: $2,021,040). Anatara is prioritising research and development and commercial development with investment increasing in both areas. General and administrative expenditure was 30% lower than the previous corresponding period.
Please click here to view the ASX announcement.
|
|
|
|
|
|
|
|
|
